Research Focus
In bipolar disorder, genetic polymorphisms shape the episodic nature of the illness and treatment response. Polymorphisms in BDNF and ANK3 genes may affect the response to mood stabilizers such as lithium. Furthermore, CYP450 enzyme variants (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4) play a critical role in drug metabolism and individual treatment compliance.
The Bipolar Working Group, which operates within the Center for Personalized Treatment (KİMER), continues its work with an innovative vision aiming to analyze the genetic and pharmacogenetic basis of Bipolar disease. This group focuses on the following objectives with the aim of developing individualized treatment strategies:
Goals of the Working Group:
- Pharmacogenetic Perspective: To investigate the role of genetic variations affecting the response to mood stabilizers in bipolar disorder.
- Genetic Predisposition: To identify genetic variations that confer risk for bipolar disorder and create models that can provide risk prediction.
- Clinical Applications: To develop genetic-based personalized treatment panels that can be used in the treatment of bipolar.
These focal points have both scientific and clinical potential for the individualized treatment of Bipolar. By integrating genetic data into clinical practice, the working group aims to develop strategies that optimize each individual's response to treatment.